Labinger out as Checkmate CEO
Plus: Travecta, MTS Health Partners, Elevar and Y Combinator
With shares of cancer company Checkmate Pharmaceuticals Inc. (NASDAQ:CMPI) down 74% year-to-date, Barry Labinger is leaving as president and CEO. Alan Fuhrman, a director, has been appointed as Checkmate’s interim president and CEO as the company seeks a permanent replacement.
Travecta Therapeutics Pte. Ltd., hired Donald Manning as CMO and head of R&D, Peter Milligan as CFO, and Peter Tate as head of Singapore operations and senior director of business development. Manning was CMO at Adynxx Inc. (NASDAQ:ADYX) and Shinogi Inc. Milligan joins from Melinta Therapeutics Inc., where he was CFO; and Tate led analytical chemistry, logistics and pharmaceutical development teams at EMD Serono Inc. Travecta is developing therapies that can cross the blood-brain and blood-retinal barriers...